Brazil’s Blau Farmacêutica Profit Drops 34% on Tender Delay but Biotech Pipeline Accelerates

2026-03-18 - 12:50

3 Key Points —Blau Farmacêutica posted recurring net income of R$37 million ($7M) in Q4 2025, a 34.4% year-over-year decline, with recurring EBITDA falling 41.2% to R$69 million ($13M) — both dragged down by a delayed federal hospital tender that pushed expected Q4 deliveries into Q1 2026, cutting net revenue 14.6% to R$389 million ($74M).